ストックスクリーナーアプリを入手
0.3269
0.93%
0.0059
IGC Pharma Inc (IGC) 最新ニュース
IGC Stock Price, Quote & Chart | IGC PHARMA INC (NYSEARCA:IGC) - ChartMill
MSN Money - MSN
Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification - marketscreener.com
FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification - Sahm
Cannabinoid Clinical Trials See Significant Growth for New… - Hemp Gazette
Cannabinoid Clinical Trials Gain Momentum: 50+ Companies Le… - Hemp Gazette
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase - BioSpace
As Alzheimer’s trial nears completion, IGC turns to caregivers - Stock Titan
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global - Scott Coop
Analysts Are Bullish on Top Healthcare Stocks: IGC Pharma (IGC), 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion - itemonline.com
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia - Times Argus
IGC Should I Buy - Intellectia AI
IGC Pharma Inc. (IGC) posts narrower than expected Q1 2026 loss, reports 5.5 percent year over year revenue decline.Crowd Sentiment Stocks - UBND thành phố Hải Phòng
IGC Pharma (IGC) Stock: Why Competitive Advantage (Slight Downtick) 2026-04-22Reversal Picks - Cổng thông tin điện tử tỉnh Lào Cai
ETFs Investing in IGC Pharma, Inc. Stocks - TradingView
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA - GuruFocus
IGC Expands Clinical Trials with New Site in Dallas - GuruFocus
Alzheimer's agitation study adds Dallas center as enrollment nears finish - Stock Titan
IGC Pharma Secures New Promissory Note Financing Agreements - The Globe and Mail
IGC Pharma (IGC) Stock: Risk vs Reward (Underperforming) 2026-04-20Wall Street Picks - Xã Châu Thành
IGC Pharma Adds $514,000 in 12% Notes From FirstFire and Vanquish Funding - TradingView
Convertible note deals give IGC Pharma (NYSE: IGC) new funding - Stock Titan
IGC Gains Approval for Psilocybin Research in Colombia - GuruFocus
New Colombia authorization lets IGC study psilocybin for dementia symptoms - Stock Titan
IGC Pharma (IGC) price target increased by 10.34% to 4.08 - MSN
India Globalization Capital Inc (IGC) - Minichart
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM ESTShow #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Viv - ChartMill
IGC Advances Patient Enrollment in Alzheimer's Clinical Trial - GuruFocus
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout - Newswire.com
What is IGC Pharma Incs valuation compared to sector2026 Fundamental Recap & Reliable Breakout Forecasts - baoquankhu1.vn
IGC Pharma, Inc. announced that it has received $0.307 million in funding - marketscreener.com
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX) - Scott Coop
New to The Street Broadcasts on Bloomberg TV, Featuring IGC, VVOS, ACXP, and EQX - National Today
IGC Pharma Share Price Target and Forecast - Investing.com India
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts - 富途牛牛
IGC Pharma (NYSEAMERICAN:IGC) Given New $5.25 Price Target at Ascendiant Capital Markets - Defense World
IGC Pharma, Inc. announced that it expects to receive $0.307 million in funding - marketscreener.com
0.78%
3.99%
大文字化:
|
ボリューム (24 時間):